The MACE risk associated with initiating ustekinumab is comparable to that of adalimumab, etanercept, and secukinumab in patients with PsO or PsA.

She started treatment with etanercept (Enbrel ®) 1 month previously. One day after a subcutaneous injection into the left thigh, she developed a mildly pruritic eruption on the right thigh ...

Biogen Inc. (NASDAQ:BIIB – Get Free Report) has been given a consensus rating of “Hold” by the thirty-one brokerages that are ...

Johnson & Johnson has reported positive results from a Phase IIIb trial of Tremfya (guselkumab) for active psoriatic ...

MoonLake Immunotherapeutics showed strong performance with sonelokimab, outperforming competitors in clinical trials. Check ...

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by Argus from a “buy” rating to a “hold” rating in a report released on ...